{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-038803","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.717066+00:00","generated_at":"2026-06-11T21:39:43.192120+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ADMA Biologics raises FY2023 revenue guidance to >$240M; Q2 revenue up 77% to $60.1M","bullets":["Q2 2023 total revenues $60.1M (+77% YoY); gross margin 27.8% (vs. 22.9% Q2 2022); normalized margin 31-32% excl. IT disruption.","Adjusted EBITDA $6.4M vs. -$6.3M YoY; net loss narrowed to $6.4M from $13.8M; adjusted net loss $3.6M.","FY2023 revenue guidance raised to at least $240M (from $220M); FY2024 raised to $275M; FY2025 to $325M+.","Nonrecurring IT disruption charge of $2.8M in COGS; production has resumed; # of FDA-licensed plasma centers on track for 10 by year-end.","Terminated financial advisory agreement with Morgan Stanley; continues to evaluate strategic alternatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-038803","json":"https://secwatch.observer/filing/0001140361-23-038803.json","markdown":"https://secwatch.observer/filing/0001140361-23-038803.md","text":"https://secwatch.observer/filing/0001140361-23-038803.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123038803/0001140361-23-038803-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123038803/brhc20057230_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:39:43.192120+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f81a41c64a76cf2b11407fd002ec83658bdb197","claim":"ADMA BIOLOGICS, INC. reported the three months ended June 30, 2023 results: revenue $60.1 Million. Guidance raised.","evidence_excerpt":"2 brhc20057230_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update 2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA(1) of $6.4 Million, a 160% Q-o-Q Improvement 2Q2023 Adjusted Net Loss(2) of $3.6 Million, a 74% Y-o-Y Improvement FY2023 Total","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123038803/0001140361-23-038803-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended June 30, 2023"},{"label":"Revenue","value":"$60.1 Million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9b8aa10c3d83d7983bcd89d5caf899d66cdee7f8","claim":"ADMA BIOLOGICS, INC. reported FY2023 results: revenue $240 Million. Guidance raised.","evidence_excerpt":"FY2023 Total Revenue Now Expected to Exceed $240 Million, Increased from $220 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123038803/0001140361-23-038803-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY2023"},{"label":"Revenue","value":"$240 Million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"a4a0c2b28d280caab64f15501d2060aff29ea129","claim":"ADMA BIOLOGICS, INC. reported FY2025 results: revenue $325 Million. Guidance raised.","evidence_excerpt":"FY2024 and 2025 Total Revenue Guidance Increased to $275 Million and $325 Million or More, Respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123038803/0001140361-23-038803-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY2025"},{"label":"Revenue","value":"$325 Million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"e4a4561b941564c337fdc24502edad94cd025f50","claim":"ADMA BIOLOGICS, INC. reported FY2024 results: revenue $275 Million. Guidance raised.","evidence_excerpt":"FY2024 and 2025 Total Revenue Guidance Increased to $275 Million and $325 Million or More, Respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123038803/0001140361-23-038803-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY2024"},{"label":"Revenue","value":"$275 Million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}